Efficacy in generalised epilepsy
How efficacious is Keppra as an adjunct?
Anoro Ellipta 20 mcg
has been lorem added to your basket
Keppra achieved significantly better retention than CBZ in patients with focal epilepsy as a monotherapy1
Time to withdrawal of allocated treatment1
A Cochrane review of monotherapy RCTs in adults or children with focal seizures or generalised tonic-clonic seizures (with or without other generalised seizure types) to assess time to withdrawal of allocated treatment (n=11,978). The above graph indicates direct and indirect evidence (network meta-analysis) of 8 AEDs as compared with CBZ in patients with focal epilepsy.1
Figure reproduced with permission from Nevitt SJ, et al. Cochrane Database Syst Rev 2017, Issue 12. Art. No.: CD011412. © Copyright 2017 The Cochrane Collaboration. Reprinted with permission from John Wiley and Sons.
AED: anti-epileptic drug; CBZ: carbamazepine; CI: confidence interval; RCT: randomised controlled trial; SD: study design.
GSK shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of information provided herein.
For safety information on GSK products or to report an Adverse Event, please contact the toll free line
0800 CALL GSK (0800 2255 475) or email email@example.com
Full prescribing information is available on request on www.gskpro.com
Please note that it may take up to 10 days to process your request. If you need further assistance contact
GSK House, 1 Industrial Avenue llupeju, Lagos or via email at firstname.lastname@example.org
GlaxoSmithKline Pharmaceutical Nigeria Ltd, 1 Industrial Avenue, llupeju, Lagos 234-1-271 1000
©2020 GSK group of companies or its licensor
Trade marks are owned by or licensed to the GSK group of companies
Keppra is a registered trademark of the GlaxoSmithKline group of companies
PM-NG-LVT-WCNT-200004 Date of preparation: November 2020.